Microbial growth tests in anti-neoplastic injectable solutions

Area of Science:

• Clinical Pharmacy
• Pharmaceutical Manufacturing
• Quality Control

Background:

• The Institut Gustave-Roussy (IGR) Department of Clinical Pharmacy (DCP) prepares approximately 30,000 therapeutic batches of anti-neoplastic agents annually.
• Postproduction quality control is performed using High-Performance Thin-Layer Chromatography (HPTLC).
• Despite ISO 9001:2000 certification, further quality improvements were sought for manufactured batches.

Purpose of the Study:

• To assess the viability of micro-organisms in anti-neoplastic agents.
• To demonstrate the lack of contamination during the manufacturing process within an isolator.
• To ensure the sterility of manufactured therapeutic batches.

Main Methods:

• Microbial viability testing was conducted using bacteria and fungi.
• Sterile media containing anti-neoplastic agents at therapeutic concentrations were used.
• Incubation was performed for 14 days to assess contamination.

Main Results:

• The study demonstrated the absence of microbial contamination in the manufactured batches.
• No growth of bacteria or fungi was observed after 14 days of incubation.
• The manufacturing process within the sterile isolator proved effective in preventing contamination.

Conclusions:

• The use of sterile drugs and sterile medical devices within a sterile isolator ensures the production of sterile therapeutic batches.
• The manufacturing process provides a high level of confidence in the sterility of anti-neoplastic agent batches.
• The implemented quality control measures effectively maintain batch integrity and patient safety.